A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
about
Vaccines: from empirical development to rational designProtective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccineB Cells and Functional Antibody Responses to Combat InfluenzaChallenges and future in vaccines, drug development, and immunomodulatory therapyH1N1, but not H3N2, influenza A virus infection protects ferrets from H5N1 encephalitis.Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity.Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.Development of clade-specific and broadly reactive live attenuated influenza virus vaccines against rapidly evolving H5 subtype viruses.Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaquesMassive mobilization of dendritic cells during influenza A virus subtype H5N1 infection of nonhuman primatesM2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.Influenza vaccines: challenges and solutions.Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses.Protein engineering strategies for the development of viral vaccines and immunotherapeutics.Bioengineering virus-like particles as vaccines.Biomolecular engineering of virus-like particles aided by computational chemistry methods.Use of computational and recombinant technologies for developing novel influenza vaccines.Expression and Purification of Virus-like Particles for Vaccination.Strategies to induce broadly protective antibody responses to viral glycoproteins.Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.Vaccine approaches conferring cross-protection against influenza viruses.Experimental adaptation of an influenza H5HA strain confers respiratory droplet transmission to reassortant H5H/H1N1 virus strain in ferrets.Towards a universal influenza vaccine: different approaches for one goal.Novel Platforms for the Development of a Universal Influenza Vaccine.Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses
P2860
Q21089599-7006EE31-2370-41CC-A544-10A29667038BQ21131325-1C29684A-187A-4FED-8CD4-6FFB94E031CDQ26801639-74D232D8-4861-4C95-B847-0A8B4924D3CDQ26853354-9B0D5E02-2FCB-441D-B194-30D560626174Q30357273-A12C10F9-206F-4226-9AAE-6F1AD9203A92Q30371649-FE70A973-D29C-4D96-A7E4-2F0A5758EDD1Q30372274-A487F58C-651E-4BAA-8B3A-1E3D676ABB47Q30372479-4440ED1D-0EF7-427D-B2F1-CDF3134003AEQ30376724-2B187537-D2DE-4197-8F1F-E1D008F05AA1Q30384878-3AA9B84A-80BB-43E1-A4CC-E7AD0D472520Q30401838-E2479B92-A577-4F21-A93C-D1D155CC4540Q30427950-4ABB745E-E7E8-4B17-A2A3-D1AD0D9A4DF7Q33684365-DA05F755-FBB0-4E00-B88D-E2074E29B2B7Q34634610-73ADFCF0-D401-4119-BCE9-C9242F0EB535Q35184572-428B2B8D-D219-42B1-80EE-802E8ED75C3CQ35808262-A8167087-FF83-4368-A4A4-F3097E096BBBQ37625877-63F4C488-4163-4D0A-80A5-376BD364F4ADQ38172045-37B0BF7A-3F9B-46FD-82B1-3A322BDF8F83Q38588882-BED5B77E-5D7B-47D8-B301-02CBD3A50479Q38643466-CC6E853A-2733-4A04-919C-425CB45E1E58Q38765283-3F7FF186-37A7-4898-A86C-2C5BCE2DEB10Q39170802-B0C666EE-7D50-40F7-8C03-9F3A14030315Q41924161-CD1A9667-EC74-4220-B6D6-DB2A8D453025Q41934895-46D7D4C3-DFAB-407C-808D-F75E39948E28Q45352757-B012B7A3-B30D-490B-A4BF-E1A19ACE7AFEQ47548866-E79CF5F6-A860-4B5F-B216-60AE2CB179F6Q52599675-BDDF5C94-766C-46FA-BC4F-589FCE2F27FAQ59126472-8266F422-C937-49D2-80FC-5E34BC5B14F1
P2860
A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A computationally optimized he ...... primates from H5N1 infection.
@ast
A computationally optimized he ...... primates from H5N1 infection.
@en
type
label
A computationally optimized he ...... primates from H5N1 infection.
@ast
A computationally optimized he ...... primates from H5N1 infection.
@en
prefLabel
A computationally optimized he ...... primates from H5N1 infection.
@ast
A computationally optimized he ...... primates from H5N1 infection.
@en
P2093
P2860
P356
P1476
A computationally optimized he ...... primates from H5N1 infection.
@en
P2093
Brendan M Giles
Clayton A Wiley
Corey J Crevar
Donald M Carter
Stacey Schultz-Cherry
Stephanie J Bissel
Ted M Ross
P2860
P304
P356
10.1093/INFDIS/JIS232
P407
P577
2012-03-23T00:00:00Z